1. A 54-year-old woman has been stable on amitriptyline 100 mg nightly for 14 months for treatment-resistant depression. A plasma level drawn at steady state reports amitriptyline at 145 ng/mL and a second compound at 98 ng/mL, for a combined value of 243 ng/mL. She is asymptomatic. Her psychiatrist adds bupropion for residual fatigue. Six weeks later she develops confusion, urinary hesitancy, tachycardia at 112 bpm, and dry mouth. A repeat level shows amitriptyline at 180 ng/mL and the second compound at 142 ng/mL, combined 322 ng/mL. Which of the following best integrates the metabolic relationship between the two measured compounds, the pharmacological significance of monitoring both, and the most likely mechanism of the clinical deterioration?

• A) The second compound is clomipramine, a distinct tertiary amine TCA that is co-prescribed at sub-therapeutic doses as an augmentation strategy; bupropion inhibits CYP1A2, the primary enzyme for clomipramine clearance, raising both compounds simultaneously and producing additive anticholinergic toxicity at the elevated combined level
• B) The second compound is amitriptyline N-oxide, a phase I oxidation product of amitriptyline with partial muscarinic receptor agonist activity; bupropion inhibits the aldehyde oxidase responsible for N-oxide reduction back to amitriptyline, causing N-oxide accumulation that adds cholinergic stimulation paradoxically to the anticholinergic amitriptyline effect
• C) The second compound is 10-hydroxyamitriptyline, a CYP3A4-mediated hydroxylation product without pharmacological activity; bupropion inhibits CYP3A4, reducing hydroxylation and driving more amitriptyline into the active parent pathway, raising amitriptyline concentrations without affecting the pharmacologically inactive metabolite level
• D) The second compound is nortriptyline, the active secondary amine metabolite produced by CYP2D6-mediated N-demethylation of amitriptyline; both parent and metabolite contribute to pharmacological effect including muscarinic, alpha-1, and SERT/NET receptor activity; bupropion is a potent CYP2D6 inhibitor that reduces clearance of both amitriptyline and nortriptyline, raising combined concentrations to a level that produces clinically manifest anticholinergic toxicity
• E) The second compound is desipramine, which accumulates when amitriptyline undergoes spontaneous non-enzymatic ring-opening under alkaline physiological conditions; bupropion raises gastric pH through histamine H2 antagonism, accelerating this conversion and increasing desipramine concentrations; the combined anticholinergic burden of amitriptyline plus desipramine explains the toxicity

2. A 61-year-old man is switched from amitriptyline to nortriptyline because of intolerable adverse effects. His psychiatrist explains that the switch to a secondary amine will improve his tolerability profile but will not eliminate all adverse effects. The patient experienced orthostatic dizziness on rising, daytime sedation impairing his work, and dry mouth with urinary hesitancy on amitriptyline. After switching to nortriptyline at an equivalent antidepressant dose, which pattern of residual adverse effects is most consistent with nortriptyline's receptor pharmacology relative to amitriptyline?

• A) All three adverse effects resolve completely because secondary amines lack muscarinic, histamine H1, and alpha-1 adrenergic receptor binding entirely, and the adverse effect burden of TCAs is exclusively a property of the tertiary amine N-methylation pattern
• B) Orthostatic dizziness and urinary hesitancy improve substantially but sedation may persist to some degree; nortriptyline has significantly lower alpha-1 adrenergic and muscarinic receptor binding potency than amitriptyline, reducing orthostatic hypotension and anticholinergic effects, but its H1 antihistaminic potency is not eliminated and residual sedation remains possible at antidepressant doses
• C) Sedation resolves completely and orthostatic dizziness improves, but urinary hesitancy worsens because nortriptyline's relatively greater NET selectivity compared to amitriptyline produces stronger norepinephrine-mediated contraction of the urethral sphincter, compounding the residual muscarinic detrusor inhibition from a different mechanism
• D) All three adverse effects worsen initially because nortriptyline's lower lipophilicity relative to amitriptyline reduces CNS penetration, forcing dose escalation to achieve equivalent antidepressant blood levels; the higher dose required to compensate for reduced CNS entry produces greater peripheral receptor binding and more pronounced adverse effects than at the amitriptyline dose
• E) Sedation and orthostatic dizziness both worsen because nortriptyline's greater NET selectivity relative to amitriptyline produces stronger central norepinephrine enhancement that activates arousal pathways and peripheral sympathetic tone paradoxically; only the anticholinergic effects improve with the switch to the secondary amine

3. A toxicology attending is teaching a resident about sodium bicarbonate therapy in TCA overdose. The attending emphasizes that bicarbonate has two mechanistically distinct effects on TCA cardiac toxicity that are additive and that a complete explanation requires understanding both. The attending also notes a third commonly proposed mechanism -- urinary alkalinization enhancing renal excretion -- and explains why this does not contribute meaningfully in TCA overdose. Which of the following correctly describes both active mechanisms and correctly dismisses the non-contributing one?

• A) First mechanism: bicarbonate's sodium content increases the electrochemical driving force for sodium entry into myocytes during phase 0, partially compensating for channel blockade; second mechanism: alkalinization increases the ionized (cationic) fraction of TCA in blood, which binds sodium channels more tightly and paradoxically stabilizes open-channel state; dismissed: urinary alkalinization, which is non-contributory because TCAs are not filtered at the glomerulus due to their high molecular weight
• B) First mechanism: alkalinization to pH 7.45--7.55 shifts TCA molecules from the ionized cationic form toward the unionized free-base form, which has lower binding affinity for the sodium channel binding site and directly reduces channel blockade; second mechanism: the sodium load delivered by the bicarbonate solution increases the electrochemical gradient driving sodium into myocytes during phase 0 depolarization, partially overcoming channel block through driving-force compensation; the third proposed mechanism, urinary alkalinization, does contribute meaningfully and should be pursued concurrently because raising urine pH ion-traps filtered TCA and produces clinically important enhancement of total body drug elimination in overdose
• C) First mechanism: bicarbonate directly chelates TCA molecules in plasma, forming non-pharmacologically active bicarbonate-TCA complexes that cannot cross the myocardial cell membrane; second mechanism: the resulting fall in free TCA plasma concentration creates a concentration gradient that draws TCA from the sodium channel binding site back into plasma; dismissed: urinary alkalinization, which fails because TCA-bicarbonate complexes are too large to be filtered at the glomerulus
• D) First mechanism: alkalinization inhibits CYP2D6 at hepatic pH above 7.4, accelerating TCA clearance from plasma; second mechanism: bicarbonate competitively inhibits the sodium channel binding site directly through structural similarity between the bicarbonate anion and the quaternary nitrogen moiety of TCA molecules; dismissed: the sodium load mechanism, which has been disproven in controlled studies showing no ECG benefit from equivalent sodium loads delivered as hypertonic saline
• E) First mechanism: alkalinization shifts TCA from its ionized (cationic) form -- which binds more avidly to the intracellular sodium channel receptor -- toward the unionized free-base form with lower channel affinity, directly reducing channel blockade; second mechanism: the sodium load in the bicarbonate solution increases the inward electrochemical driving force for sodium across the myocyte membrane during phase 0, partially compensating for the reduced number of available channels; dismissed: urinary alkalinization, which is non-contributory because the negligible plasma fraction of a drug with Vd of 10--50 L/kg means that even maximally efficient renal clearance removes a pharmacologically insignificant fraction of total body TCA burden

4. A 48-year-old woman has been stable on nortriptyline 50 mg nightly with a plasma level of 85 ng/mL (therapeutic range 50--150 ng/mL) for ten months. Her psychiatrist adds paroxetine for a comorbid panic disorder. Eight weeks later her nortriptyline level is 260 ng/mL and she reports confusion and palpitations. A colleague suggests the elevated level reflects CYP2D6 ultra-rapid metabolizer (UM) status rather than a drug interaction. Which of the following best explains why the drug interaction hypothesis is correct and the UM hypothesis is incorrect, and predicts what would happen to the nortriptyline level if paroxetine were discontinued?

• A) The drug interaction hypothesis is correct because paroxetine is a potent CYP2D6 inhibitor that reduces nortriptyline clearance, raising plasma concentrations at an unchanged dose; the UM hypothesis is incorrect because CYP2D6 ultra-rapid metabolizers have increased enzymatic activity that would produce lower -- not higher -- plasma concentrations than expected at a given dose; discontinuing paroxetine would restore CYP2D6 activity and the nortriptyline level would be expected to fall back toward the pre-paroxetine baseline over several weeks as enzyme inhibition is relieved
• B) The drug interaction hypothesis is correct because paroxetine inhibits CYP3A4, the primary enzyme for nortriptyline hydroxylation, causing accumulation of the parent compound; the UM hypothesis is incorrect because ultra-rapid metabolizers generate excess desipramine from nortriptyline, and desipramine is not detected by the nortriptyline immunoassay; discontinuing paroxetine would require two to three weeks for CYP3A4 enzyme induction to restore baseline activity
• C) Both hypotheses are plausible; CYP2D6 UM status and paroxetine co-administration produce identical plasma concentration-time profiles and cannot be distinguished without genotyping; discontinuing paroxetine would confirm the drug interaction by producing a fall in level only if the patient is a CYP2D6 normal metabolizer, whereas the level would remain elevated in a UM regardless of paroxetine discontinuation
• D) The drug interaction hypothesis is correct because paroxetine competitively displaces nortriptyline from alpha-1-acid glycoprotein binding sites, increasing the free (unbound) fraction measured by total plasma assay; the UM hypothesis is incorrect because ultra-rapid metabolizers show no change in total plasma concentration -- only in the free fraction; discontinuing paroxetine would reduce the free fraction back to baseline but the total measured level would remain unchanged
• E) Both hypotheses are incorrect; the most likely explanation is that nortriptyline was recently reformulated by the manufacturer using a different salt form with higher bioavailability; the CYP2D6 system does not contribute meaningfully to nortriptyline clearance at therapeutic doses; paroxetine and nortriptyline have no established pharmacokinetic interaction

5. A neurologist prescribes selegiline 5 mg orally twice daily to a 68-year-old man with Parkinson's disease. The patient asks whether he needs to follow the same strict dietary tyramine restrictions his wife follows for her phenelzine. The neurologist explains that at this dose he does not need the same restrictions as his wife, and gives a mechanistic explanation connecting MAO isoform selectivity to the anatomy of tyramine first-pass metabolism. A medical student asks the neurologist to extend the explanation: if the patient's dose were eventually increased to antidepressant levels, would the dietary restriction requirement change, and why? Which of the following correctly answers both the original question and the student's extension?

• A) At 5 mg twice daily, selegiline requires no dietary restriction because it selectively inhibits MAO-B, and tyramine in food is metabolized exclusively by MAO-A in the intestinal mucosa and liver; if the dose were increased to antidepressant levels, MAO-B selectivity would be maintained because selectivity is an intrinsic molecular property of selegiline that does not change with dose, and no dietary restriction would ever be required regardless of dose
• B) At 5 mg twice daily, selegiline requires no dietary restriction because gut and hepatic MAO-A is not present in physiologically significant quantities, and tyramine clearance at these sites is handled entirely by MAO-B; if the dose were increased to antidepressant levels, dietary restriction would become necessary because higher selegiline doses begin inhibiting MAO-B at peripheral sympathetic nerve terminals where it is the dominant isoform responsible for catecholamine catabolism
• C) At 5 mg twice daily, selegiline maintains relative MAO-B selectivity, leaving intestinal mucosa and hepatic MAO-A -- the primary first-pass tyramine metabolizing enzyme -- substantially intact, so dietary tyramine continues to be extracted during gut and liver passage and does not reach systemic circulation in dangerous quantities; if the dose were increased to the range required for antidepressant effect, MAO-B selectivity is lost and MAO-A is also inhibited, impairing first-pass tyramine extraction and requiring the same dietary restrictions as non-selective irreversible MAOIs
• D) At 5 mg twice daily, selegiline requires no dietary restriction because tyramine is entirely metabolized by MAO-B in the gut lumen before it crosses the intestinal epithelium, and selegiline's MAO-B inhibition at low doses is incomplete (only 40%), leaving sufficient residual MAO-B activity for tyramine clearance; if the dose were increased to antidepressant levels, MAO-B inhibition reaches 100% and dietary restriction becomes necessary because complete gut luminal MAO-B blockade allows tyramine absorption
• E) At 5 mg twice daily, selegiline requires no dietary restriction because it is metabolized so rapidly during first-pass absorption through the gut wall that negligible systemic concentrations are achieved; the absence of systemic drug means no MAO inhibition occurs at peripheral sympathetic terminals; if the dose were increased to antidepressant levels, the first-pass extraction would become saturated and systemic exposure would increase, producing MAO inhibition at peripheral sympathetic terminals and requiring dietary restriction

6. A clinical pharmacologist presents three patients to a group of residents, each on a different MAO-inhibiting agent, and asks the group to predict -- for each patient -- the required washout interval before starting an SSRI, the dietary tyramine restriction requirement, and the mechanistic basis for both. Patient 1 is on phenelzine 45 mg daily. Patient 2 is on selegiline 5 mg orally twice daily for Parkinson's disease. Patient 3 is on moclobemide 300 mg daily (obtained from Canada). Which of the following correctly characterizes all three patients across both dimensions?

• A) Patient 1: two-week washout, strict dietary restriction -- phenelzine irreversibly inhibits both MAO-A and MAO-B; Patient 2: two-week washout, strict dietary restriction -- selegiline irreversibly inhibits MAO-B which handles all peripheral tyramine catabolism; Patient 3: 24-hour washout, minimal dietary restriction -- moclobemide reversibly inhibits MAO-A, allowing competitive tyramine displacement
• B) Patient 1: two-week washout, strict dietary restriction -- irreversible non-selective MAO inhibition, MAO-A resynthesis required for recovery; Patient 2: two-week washout, no dietary restriction -- irreversible MAO-B inhibition requires enzyme resynthesis for washout, but MAO-A integrity preserves tyramine first-pass extraction; Patient 3: 24-hour washout, minimal dietary restriction -- reversible MAO-A inhibition recovers rapidly, and competitive tyramine displacement reduces pressor response risk
• C) Patient 1: one-week washout, strict dietary restriction -- phenelzine's short plasma half-life of three days means five half-lives (15 days, rounded to one week for clinical use) determines the washout; Patient 2: 48-hour washout, no dietary restriction -- selegiline is selective for MAO-B and reversible at low doses; Patient 3: one-week washout, strict dietary restriction -- moclobemide's reversible binding requires one week for full MAO-A recovery, and tyramine restriction is required until recovery is complete
• D) Patient 1: two-week washout, strict dietary restriction -- phenelzine irreversibly inhibits both MAO isoforms via covalent FAD modification; washout determined by enzyme resynthesis time (~2 weeks), not plasma half-life; strict dietary restriction because MAO-A-mediated first-pass tyramine extraction is abolished; Patient 2: no special washout beyond standard drug clearance, no dietary restriction -- low-dose oral selegiline is relatively selective for MAO-B, leaving MAO-A first-pass tyramine metabolism substantially intact; Patient 3: 24-hour washout, minimal dietary restriction -- moclobemide reversibly inhibits MAO-A; MAO-A activity recovers within ~24 hours without enzyme resynthesis; competitive tyramine displacement partially preserves MAO-A activity during tyramine ingestion
• E) Patient 1: five-week washout, strict dietary restriction -- phenelzine produces an active metabolite phenylhydrazine with a half-life of seven days, requiring five half-lives (35 days) for full clearance; Patient 2: two-week washout, no dietary restriction -- selegiline irreversibly inhibits MAO-B only; Patient 3: two-week washout, minimal dietary restriction -- moclobemide inhibits MAO-A irreversibly but with lower affinity than phenelzine, requiring the same two-week enzyme resynthesis period but producing less complete inhibition

7. A 22-year-old man is brought to the emergency department one hour after ingesting a large quantity of his mother's doxepin. On arrival he is agitated and confused with dilated pupils, heart rate 124 bpm, and dry flushed skin. His QRS is 94 ms. Over the next 90 minutes he becomes increasingly obtunded, his QRS widens to 118 ms, and he develops a 45-second generalized tonic-clonic seizure. A nurse asks the physician to explain the clinical sequence and to confirm the treatment priorities. The physician states that the management of seizures in this setting requires a specific drug choice and an equally specific avoidance. Which of the following correctly describes the clinical progression sequence, the first-line anticonvulsant, and the agent that must be avoided and why?

• A) The clinical sequence reflects progressive H1 receptor blockade producing CNS depression followed by alpha-1 blockade producing hypotension and reflex seizures; first-line anticonvulsant is phenytoin because it has established efficacy in TCA-induced seizures through its sodium channel-blocking properties, which counteract the TCA-induced depolarization block; physostigmine should be avoided because it is hepatotoxic at doses required for effect
• B) The clinical sequence reflects a predictable progression from anticholinergic syndrome (agitation, tachycardia, dry skin, dilated pupils) through CNS depression, then QRS widening from sodium channel blockade, then seizures from combined CNS depression and lowered seizure threshold; first-line anticonvulsant is benzodiazepines (lorazepam or diazepam), which increase GABAergic inhibitory conductance without affecting cardiac conduction; phenytoin must be avoided because its own sodium channel-blocking mechanism is additive with TCA-induced cardiac sodium channel blockade and can worsen QRS prolongation and precipitate ventricular arrhythmia
• C) The clinical sequence reflects SERT inhibition producing serotonin syndrome that progresses to seizures; first-line treatment is cyproheptadine (serotonin antagonist) for the underlying mechanism rather than anticonvulsants, which treat the symptom without addressing the cause; phenytoin is acceptable once cyproheptadine has been administered because serotonin normalization removes the mechanism of cardiac sensitization
• D) The clinical sequence reflects progressive muscarinic blockade producing the anticholinergic syndrome; once QRS widening develops, physostigmine is the appropriate treatment because it reverses the muscarinic blockade responsible for both the cardiac and CNS toxicity simultaneously; benzodiazepines should be avoided because their GABA-A potentiation excessively depresses the brainstem respiratory centers in the context of already depressed consciousness
• E) The clinical sequence reflects alpha-1 adrenergic blockade producing severe hypotension and cerebral hypoperfusion leading to ischemic seizures; first-line treatment is norepinephrine infusion to restore cerebral perfusion pressure, which terminates the seizures without anticonvulsant medication; benzodiazepines and phenytoin are both contraindicated because vasodilation from these agents would worsen the hypotension driving the ischemic seizures

8. A 57-year-old woman on phenelzine is admitted for hip fracture repair. The anesthesia team considers analgesic options and also asks a clinical pharmacologist to compare two dangerous drug interactions associated with phenelzine -- the meperidine interaction and the dietary tyramine interaction -- to help the team understand why they differ in mechanism, clinical presentation, and which opioids are safe. Which of the following correctly contrasts the two interactions and identifies a safe opioid choice?

• A) The meperidine interaction produces serotonin syndrome because meperidine inhibits the serotonin transporter (SERT) in addition to its opioid receptor agonism; combined SERT inhibition and MAO-A inhibition prevents both serotonin reuptake and serotonin catabolism, producing massive serotonin accumulation that manifests as hyperthermia, agitation, and rigidity; the tyramine interaction produces a noradrenergic hypertensive crisis because MAO-A failure allows dietary tyramine to reach adrenergic nerve terminals, where it is transported by the norepinephrine transporter (NET) and displaces stored norepinephrine in massive quantities; the two interactions involve different neurotransmitters (serotonin vs. norepinephrine), different transport mechanisms (SERT vs. NET), and different exogenous triggers (a drug vs. a dietary amine); morphine lacks significant SERT inhibitory activity and does not displace norepinephrine from nerve terminals, making it a substantially safer analgesic choice
• B) The meperidine interaction and the tyramine interaction are mechanistically identical -- both involve the norepinephrine transporter (NET) transporting the substrate into adrenergic nerve terminals, where it displaces norepinephrine; meperidine and tyramine are both indirect sympathomimetics; morphine is safe because it binds the NET with lower affinity than either meperidine or tyramine, producing a smaller norepinephrine displacement per molecule
• C) The meperidine interaction produces a hypertensive crisis identical to the tyramine reaction because meperidine is an indirect sympathomimetic that accumulates to toxic concentrations when MAO-A is inhibited; the tyramine interaction produces serotonin syndrome because dietary tyramine is converted to tryptamine (a serotonin precursor) when MAO-A cannot deaminate it; fentanyl is the safe opioid because it is an MAO-A substrate that is metabolized faster than meperidine and tyramine and does not accumulate
• D) The meperidine interaction produces opioid toxicity rather than serotonin syndrome because MAO-A inhibition prevents meperidine conversion to the inactive metabolite normeperidine; accumulated meperidine produces mu-opioid receptor over-activation manifesting as miosis, respiratory depression, and bradycardia; the tyramine interaction produces alpha-1-mediated vasoconstriction from tyramine acting as a direct adrenergic agonist; tramadol is safer than meperidine because it lacks the MAO-A substrate activity
• E) Both the meperidine and tyramine interactions are mediated through the same final common pathway of alpha-2 autoreceptor stimulation at presynaptic adrenergic terminals, producing paradoxical norepinephrine release; the clinical presentations are identical; fentanyl is unsafe for the same reason as meperidine because all synthetic opioids stimulate presynaptic alpha-2 autoreceptors as a class effect at analgesic doses

9. A 46-year-old man with recurrent major depressive disorder has been on nortriptyline 75 mg nightly for eight weeks with a plasma level of 120 ng/mL and a partial antidepressant response -- improved sleep and appetite but persistent low mood and anhedonia. His psychiatrist increases the dose to 100 mg nightly. Four weeks later his plasma level is 195 ng/mL and his depression scores are worse than before the dose increase. He has no new medical problems and no new medications. The psychiatrist is puzzled by the clinical deterioration despite the higher plasma level. Which of the following correctly explains this outcome and identifies the appropriate next management step?

• A) The worsening reflects pharmacokinetic nonlinearity: nortriptyline switches from first-order to zero-order elimination above 150 ng/mL, causing disproportionate accumulation that produces a paradoxical pharmacokinetic reversal of antidepressant efficacy through competitive inhibition of SERT and NET at very high concentrations
• B) The worsening reflects CYP2D6 autoinduction by nortriptyline at higher doses; the dose increase accelerated nortriptyline's own metabolism, paradoxically lowering the free fraction available for receptor binding despite a higher total plasma concentration as measured by the immunoassay
• C) The worsening most likely reflects the development of tachyphylaxis -- complete pharmacodynamic tolerance -- to nortriptyline's monoamine reuptake inhibitory effects after eight weeks of treatment; the plasma level is irrelevant to this outcome because tolerance develops at the receptor level regardless of concentration
• D) The worsening reflects a protein binding saturation effect: above 150 ng/mL nortriptyline saturates all available alpha-1-acid glycoprotein binding sites, causing the free fraction to rise sharply and shift the drug to alpha-1 adrenergic receptors in a concentration-dependent manner, producing a pharmacological switch from antidepressant to sedative-vasodilator activity
• E) The worsening reflects nortriptyline's well-characterized curvilinear (inverted-U) plasma concentration-response relationship: antidepressant efficacy improves as concentrations rise within the therapeutic window of 50 to 150 ng/mL but decreases at concentrations above 150 ng/mL, meaning the dose increase drove the level into a range where efficacy paradoxically declines; the appropriate next step is to reduce the dose back to 75 mg nightly and recheck the plasma level, targeting the mid-therapeutic range rather than maximizing plasma concentration

10. A psychiatry resident is preparing to switch three different patients to phenelzine. Patient A has been on fluoxetine 20 mg daily for six months. Patient B has been on sertraline 100 mg daily for six months. Patient C has been on venlafaxine 150 mg daily for six months. The resident asks the attending to explain why each patient requires a different washout interval, integrating the pharmacokinetic basis for each. Which of the following correctly ranks the washout intervals from longest to shortest and correctly identifies the pharmacokinetic determinant for each?

• A) Patient A (fluoxetine): five weeks -- determined by fluoxetine's own parent-drug plasma half-life of approximately five weeks, with norfluoxetine cleared more rapidly than the parent and contributing nothing to the washout; Patient B (sertraline): two weeks -- determined by sertraline's plasma half-life of approximately 26 hours and lack of long-lived active metabolites; Patient C (venlafaxine): one week -- determined by venlafaxine's plasma half-life of approximately five hours plus desvenlafaxine's half-life of approximately eleven hours; longest-to-shortest ranking: A > B > C
• B) Patient A (fluoxetine): eight weeks -- determined by time required for SERT receptor resynthesis to baseline density after irreversible SERT inhibition by fluoxetine; Patient B (sertraline): four weeks -- sertraline has a longer active metabolite half-life than venlafaxine; Patient C (venlafaxine): two weeks -- standard washout for all SNRIs due to norepinephrine reuptake inhibition requiring longer clearance than serotonin-only agents
• C) Patient A (fluoxetine): five weeks -- norfluoxetine, fluoxetine's active metabolite, has a plasma half-life of one to two weeks, requiring approximately five weeks for both parent and metabolite to clear to sub-pharmacological concentrations; Patient B (sertraline): approximately two weeks -- sertraline has a plasma half-life of approximately 26 hours and its metabolite desmethylsertraline has modest pharmacological activity and a half-life that does not substantially extend the washout beyond two weeks; Patient C (venlafaxine): approximately one week -- venlafaxine and its active metabolite desvenlafaxine have half-lives of approximately five and eleven hours respectively, clearing within approximately one week at five half-lives of the longer species; ranking: A (5 weeks) > B (~2 weeks) > C (~1 week)
• D) All three patients require the same two-week washout because the determining factor is the time for MAO enzyme resynthesis after serotonergic suppression of MAO-A gene expression, which is uniform across all serotonergic antidepressants; the identity of the stopped drug is clinically irrelevant to the washout calculation
• E) Patient A (fluoxetine): three weeks -- fluoxetine undergoes zero-order elimination due to CYP2D6 saturation, extending clearance by approximately one week beyond the standard two-week period; Patient B (sertraline): two weeks -- standard washout; Patient C (venlafaxine): three weeks -- desvenlafaxine's active noradrenergic properties require an additional week of washout beyond the serotonergic clearance period to protect against noradrenergic-MAOI hypertensive interaction

11. A 78-year-old man with major depressive disorder and a history of a fall-related hip fracture is brought to a geriatric psychiatry consultation. His primary care physician has been considering amitriptyline for depression and chronic pain. The consulting geriatric psychiatrist explains that TCAs are listed in the Beers Criteria as potentially inappropriate medications for older adults, and that the concern is not simply that TCAs have side effects -- it is that the physiological changes of aging specifically amplify two receptor-mediated risks that are well tolerated in younger patients at the same dose. Which of the following correctly identifies both receptor systems, the specific age-related physiological changes that amplify each risk, and integrates this into an explanation of why a dose of amitriptyline tolerated by a 45-year-old is potentially dangerous in a 78-year-old?

• A) Muscarinic receptor blockade produces anticholinergic toxicity -- confusion, urinary retention, constipation -- that is amplified in older adults by age-related reduction in CNS cholinergic neuronal reserve (making the brain more vulnerable to additional anticholinergic burden), increased prevalence of pre-existing genitourinary outflow obstruction, and reduced baseline gut motility; alpha-1 adrenergic receptor blockade produces orthostatic hypotension that is amplified by age-related impairment of baroreceptor reflex sensitivity, reduced cardiovascular reserve and compensatory capacity, and polypharmacy with concurrent antihypertensives and diuretics that compound the hypotensive effect -- the combined result is that a 45-year-old who experiences mild dry mouth and a small orthostatic blood pressure drop on amitriptyline may become the 78-year-old who develops acute urinary retention, falls-induced hip fracture, and anticholinergic delirium on the same dose
• B) Histamine H1 receptor blockade produces sedation that is amplified in older adults by age-related reduction in cytochrome P450 metabolic capacity, causing the same dose to produce higher plasma concentrations and greater H1 receptor occupancy in elderly patients than in younger ones; serotonin transporter (SERT) inhibition produces platelet dysfunction that is amplified in older adults by the higher prevalence of concurrent antiplatelet and anticoagulant use, creating an additive bleeding risk that is the primary safety concern driving the Beers Criteria listing
• C) Alpha-1 adrenergic receptor blockade produces orthostatic hypotension that is amplified only in patients over 80 due to complete loss of baroreflex function after age 80; muscarinic receptor blockade produces confusion only in patients with pre-existing dementia, and the Beers Criteria listing therefore applies exclusively to elderly patients who have both risk factors simultaneously rather than to all patients over 65
• D) Beta-1 adrenergic receptor blockade by TCAs produces bradycardia and reduced cardiac output that is amplified in elderly patients by age-related reduction in intrinsic heart rate; muscarinic receptor blockade causes urinary retention that is amplified by age-related reduction in renal blood flow and glomerular filtration rate; together these mechanisms produce the falls-and-fractures risk that the Beers Criteria addresses
• E) The Beers Criteria listing for TCAs in older adults is based exclusively on the QTc-prolonging effects of TCAs, which are amplified in older patients by age-related reduction in cardiac repolarization reserve; neither muscarinic nor alpha-1 adrenergic receptor pharmacology contributes meaningfully to the geriatric safety concern because these receptor systems become less sensitive with age, reducing rather than amplifying the peripheral adverse effects

12. A psychiatrist is explaining the selegiline transdermal patch (Emsam) prescribing rules to a resident. She notes that the FDA-approved labeling has an unusual feature: dietary tyramine restrictions are not required at the 6 mg per 24 hours dose but are required at the 9 mg and 12 mg per 24 hours doses. The resident asks for a mechanistic explanation that accounts for the dose-dependent emergence of the dietary restriction requirement, integrating what happens differently at the lower versus higher transdermal doses with respect to first-pass gut and liver MAO-A. Which of the following correctly explains this dose-dependent dietary restriction threshold?

• A) At 6 mg per 24 hours, transdermal selegiline is absorbed too slowly to achieve systemic concentrations sufficient for any MAO inhibition; the antidepressant effect at this dose is achieved through a non-MAO mechanism involving dopamine D2 receptor partial agonism; at 9 and 12 mg per 24 hours, MAO inhibition begins, and dietary restriction becomes necessary only when MAO inhibition reaches a threshold of approximately 70% of total body MAO activity
• B) At 6 mg per 24 hours, the transdermal patch delivers drug that is immediately inactivated in dermal tissue by local monoamine oxidase before reaching the systemic circulation; only a small fraction escapes dermal MAO to produce minimal systemic MAO inhibition; at 9 and 12 mg per 24 hours, dermal MAO is saturated and the drug reaches the systemic circulation in quantities that also inhibit gut MAO-A
• C) At all transdermal doses, selegiline maintains complete MAO-B selectivity, never inhibiting MAO-A regardless of systemic concentration; dietary restriction at 9 and 12 mg per 24 hours is required not because of MAO-A inhibition but because selegiline's amphetamine metabolites at higher doses act as indirect sympathomimetics that mimic tyramine's pressor effect independently of MAO status
• D) At 6 mg per 24 hours, the transdermal route delivers selegiline systemically while largely bypassing first-pass exposure of gut and liver MAO-A, leaving intestinal and hepatic MAO-A substantially intact to metabolize ingested tyramine during its first-pass transit; at 9 and 12 mg per 24 hours, the systemic selegiline concentrations achieved are sufficient to inhibit MAO-A at peripheral sympathetic nerve terminals throughout the body, including at a level that impairs tyramine-induced norepinephrine release regulation, making dietary restriction necessary even though gut-level first-pass MAO-A may still retain partial activity
• E) At 6 mg per 24 hours, the FDA exemption from dietary restriction reflects a regulatory decision based on pharmacovigilance data showing no reported hypertensive crises rather than a pharmacodynamic mechanism; at 9 and 12 mg per 24 hours, the restriction is reintroduced conservatively because post-marketing data were insufficient to confirm continued safety at higher doses, not because a pharmacodynamic threshold has been crossed

13. A nephrology fellow is called to consult on a patient with severe imipramine overdose, QRS 132 ms, currently receiving sodium bicarbonate infusion with partial QRS narrowing to 118 ms. The fellow proposes adding hemodialysis and asks the toxicologist on the case to explain: (1) why hemodialysis will not meaningfully accelerate imipramine removal despite working well for other drug overdoses, and (2) whether urinary alkalinization -- which the fellow also proposes -- would add benefit on top of the systemic alkalinization being achieved by the bicarbonate infusion. Which of the following correctly addresses both questions with the appropriate pharmacokinetic reasoning?

• A) Hemodialysis is ineffective because imipramine undergoes phase II conjugation before renal elimination, and conjugated metabolites are too polar to pass through dialysis membranes; urinary alkalinization would add significant benefit because it traps ionized imipramine in the renal tubule, and because imipramine has a renal excretion fraction of approximately 40% of total clearance, alkalinizing urine substantially accelerates elimination
• B) Hemodialysis is ineffective because imipramine's volume of distribution of approximately 10 to 30 liters per kilogram means that only a negligible fraction of total body drug resides in the plasma compartment at any moment -- even perfect dialytic clearance of plasma removes a pharmacologically irrelevant quantity of the massive tissue-sequestered drug burden; urinary alkalinization adds no meaningful benefit for the same reason: the plasma fraction is so small that even maximally efficient renal excretion of ionized drug from plasma removes a clinically insignificant portion of total body imipramine
• C) Hemodialysis is ineffective because imipramine is a large hydrophilic molecule (molecular weight greater than 1,000 daltons) that cannot pass through standard high-flux dialysis membranes; urinary alkalinization would add significant benefit because imipramine's renal tubular reabsorption is pH-dependent and alkalinization substantially increases the fraction excreted unchanged in urine, accelerating total body clearance
• D) Hemodialysis is effective for imipramine removal and should be initiated emergently; the toxicologist is incorrect to oppose dialysis; urinary alkalinization adds no benefit because imipramine is a strong acid that is already predominantly ionized at physiological urine pH, leaving no additional ionization possible through further alkalinization
• E) Hemodialysis is ineffective because imipramine irreversibly binds to dialysis membrane proteins, fouling the membrane within minutes of initiating the run; urinary alkalinization adds benefit equivalent to sodium bicarbonate infusion because both routes of alkalinization reduce TCA sodium channel binding affinity through the same pH-dependent mechanism, and combining systemic and urinary alkalinization achieves a synergistic pH elevation that bicarbonate infusion alone cannot